Skip to main content

Table 1 Baseline patient characteristics

From: Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure

Variables Group I (AmB+ Fluconazole Group II (AmB+ Fluconazole P-value
+ 5-FC,n = 27) + 5-FC + VPS, n = 39)
Age, years (mean ± SD) 44.1 ± 14.0 47.9 ± 14.7 0.287
Gender, male (n,%) 20 (74.1%) 28 (71.8%) 0.839
Predisposing Factors
 Chronic hepatitis B 5 (18.5%) 4 (10.3%) 0.340
 Pulmonary tuberculosis 3 (11.1%) 2 (5.1%) 0.370
 Type 2 diabetes mellitus 2 (7.4%) 5 (12.8%) 0.486
 Autoimmune diseases 1 (3.7%) 4 (10.3%) 0.326
 Solid tumor 1 (3.7%) 4 (10.3%) 0.326
Symptoms duration, days, (med, range) 30 (6–120) 30 (8–90) 0.331
Length of hospital stay days, (med, range) 77 (12–308) 35 (18–73) 0.000*
CSF parameters opening pressure
 ≥25 cmH2O(n, %) 27 (100%) 42 (93.0%) 0.107
 CSF WBC count×106/l (med, range) 92 (10–649) 82 (4–840) 0.744
 ≥20 (n,%) 23 (85.2%) 32 (82.1%) 0.871
 CSF protein g/l (med, range) 0.78 (0.08–2.58) 0.71 (0.22–5.10) 0.579
 CSF glucose mmol/l (med, range) 1.19 (0.00–3.79) 0.83 (0.01–3.09) 0.273
 CSF cryptococci count/ml (med, range) 1398 (0–57,500) 9533 (0–263,000) 0.002*
 CSF culture positive (+) 15 (55.69%) 19 (48.7%) 0.114
Brain images (CT or MRI)
 Meningeal enhancement 18 (66.7%) 18 (46.2%) 0.182
 Cryptococcosis-related lesions in brain 13 (48.1%) 17 (43.6%) 0.717
 Hydrocephalus 3 (11.1%) 3 (7.7%) 0.637
BMRC staging (n, %)    0.443
 1 2 (7.4%) 8 (20.5%)  
 2 16 (59.3%) 10 (25.6%)  
 3 9 (33.3%) 21 (53.8%)  
  1. AmB amphotericin B, 5-Fc flcytosine, VPS ventriculoperitoneal shunts, WBC white blood cell, SD standard deviation, med median, CSF cerebrospinal fluid, BMRC British Medical research council. Data are presented as the mean ± sD, median (range) or n (%). Continuous variables were analyzed by t-test or Wilcoxon rank sum test; categorical variables were analyzed by Chi-square test or Fisher’s exact test.
  2. *P < 0.05